Global Cell and Gene Therapy CDMO Market Strategic Research Report

The global cell and gene therapy contract development and manufacturing organization (CDMO) market represents one of the most capital-intensive and scientifically demanding segments within the life sciences outsourcing industry. Valued at approximately USD 5.8 billion in 2024, the market has emerged as a critical enabler of the broader advanced therapy medicinal product (ATMP) ecosystem, providing specialized capabilities in viral vector manufacturing, cell processing, plasmid DNA production, and fill-finish operations that most emerging biotechnology sponsors lack the infrastructure or expertise to execute in-house. With over 2,500 cell and gene therapy clinical programs globally at various stages of development and a growing roster of approved products including CAR-T cell therapies and adeno-associated virus (AAV)-based gene therapies, the demand for outsourced manufacturing capacity has intensified markedly, placing premium value on CDMOs that can bridge the persistent gap between laboratory-scale innovation and commercial-scale production.

Several converging forces are accelerating market expansion. First, the exponential growth in ATMP clinical pipelines—driven by continued investment from both venture capital and large pharmaceutical companies—has consistently outpaced internal manufacturing buildout, compelling sponsors at all stages to rely on CDMOs for process development and GMP manufacturing. Second, the commercial approval trajectory is steepening: regulatory agencies including the FDA and EMA have approved over 30 cell and gene therapy products as of 2024, each creating recurring commercial manufacturing demand that extends well beyond the clinical supply phase. Third, advances in manufacturing process intensification—including single-use bioreactor systems, suspension-adapted cell culture platforms, and in-line analytical technologies—are enabling CDMOs to materially reduce cost of goods while improving batch consistency, making outsourcing more economically attractive even for sponsors with partial internal capacity. A meaningful restraint, however, is the persistent shortage of specialized scientific and technical workforce skilled in vector biology, aseptic processing, and ATMP-specific quality systems, which constrains capacity additions and inflates labor costs across the sector.

This report provides a comprehensive, data-anchored assessment of the global cell and gene therapy CDMO market spanning the forecast period 2025 to 2032, with 2024 as the base year. The analysis covers market segmentation by service type—including viral vector manufacturing, cell therapy manufacturing, plasmid DNA production, and process development—as well as by end-use application across oncology, rare genetic disorders, cardiovascular disease, and ophthalmology indications. Regional forecasts encompass North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, with country-level granularity for the United States, Germany, the United Kingdom, Japan, China, and South Korea. Corporate strategy teams evaluating partnership models, investment analysts assessing capacity expansion plays, M&A advisors screening acquisition targets, and procurement managers benchmarking CDMO capabilities will find this report an essential decision-support resource.